Roche announced that the U.S. FDA has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent Influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis. “With today’s […]

The post Roche Announces Fda approval of Xofluza for the prevention of influenza following contact with an infected person first appeared on World Pharma Today.